One-Year Results of 0.01% and 0.05% Atropine Eye Drops in Childhood Myopia Progression.

IF 1 4区医学 Q4 OPHTHALMOLOGY

Journal of Pediatric Ophthalmology & Strabismus Pub Date : 2025-03-26 DOI:10.3928/01913913-20250227-07

Sibel Coşkun Akdemir, Irfan Akalın, Betul Önal Günay

{"title":"One-Year Results of 0.01% and 0.05% Atropine Eye Drops in Childhood Myopia Progression.","authors":"Sibel Coşkun Akdemir, Irfan Akalın, Betul Önal Günay","doi":"10.3928/01913913-20250227-07","DOIUrl":null,"url":null,"abstract":"Purpose: To compare 0.01% and 0.05% atropine eye drops with every other day treatment for slowing myopia progression in children.Methods: Children aged 5 to 15 years who had myopia of -1.00 to 8.00 diopters (D), astigmatism less than -2.50 D, and myopic progression of at least 1.00 D in the past year were included in the retrospective study. The 0.01% and 0.05% atropine eye drops were applied every other day. At each visit, all patients underwent complete ophthalmic examination including cycloplegic refraction, axial length (AL), and photopic-mesopic pupil sizes. Spherical equivalent (SE), AL, and photopicmesopic pupil sizes were evaluated.Results: In total, 92 eyes of 46 patients were included in the study (22 in the 0.01% atropine group and 24 in the 0.05% atropine group). At the end of the 12-month follow-up period, the mean SE changes were -0.41 ± 0.28 and -0.19 ± 0.22 D in the 0.01% and 0.05% atropine groups, respectively (P < .001). The AL changes were 0.19 ± 0.16 and 0.16 ± 024 mm in the 0.01% and 0.05% atropine groups, respectively (P = .52). Side effects such as photophobia and blurred near vision were not observed in the 0.01% atropine group, but in the 0.05% atropine group, photophobia was observed in 3(12.5%) cases and blurred near vision was observed in 8 (33%) cases.Conclusions: The 0.01% and 0.05% atropine eye drops significantly slowed the progression of myopia with every other day use. The 0.01% atropine was better tolerated than 0.05% atropine. [J Pediatr Ophthalmol Strabismus. 20XX;X(X):XXX-XXX.].","PeriodicalId":50095,"journal":{"name":"Journal of Pediatric Ophthalmology & Strabismus","volume":" ","pages":"1-6"},"PeriodicalIF":1.0000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Ophthalmology & Strabismus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/01913913-20250227-07","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare 0.01% and 0.05% atropine eye drops with every other day treatment for slowing myopia progression in children.

Methods: Children aged 5 to 15 years who had myopia of -1.00 to 8.00 diopters (D), astigmatism less than -2.50 D, and myopic progression of at least 1.00 D in the past year were included in the retrospective study. The 0.01% and 0.05% atropine eye drops were applied every other day. At each visit, all patients underwent complete ophthalmic examination including cycloplegic refraction, axial length (AL), and photopic-mesopic pupil sizes. Spherical equivalent (SE), AL, and photopicmesopic pupil sizes were evaluated.

Results: In total, 92 eyes of 46 patients were included in the study (22 in the 0.01% atropine group and 24 in the 0.05% atropine group). At the end of the 12-month follow-up period, the mean SE changes were -0.41 ± 0.28 and -0.19 ± 0.22 D in the 0.01% and 0.05% atropine groups, respectively (P < .001). The AL changes were 0.19 ± 0.16 and 0.16 ± 024 mm in the 0.01% and 0.05% atropine groups, respectively (P = .52). Side effects such as photophobia and blurred near vision were not observed in the 0.01% atropine group, but in the 0.05% atropine group, photophobia was observed in 3(12.5%) cases and blurred near vision was observed in 8 (33%) cases.

Conclusions: The 0.01% and 0.05% atropine eye drops significantly slowed the progression of myopia with every other day use. The 0.01% atropine was better tolerated than 0.05% atropine. [J Pediatr Ophthalmol Strabismus. 20XX;X(X):XXX-XXX.].

查看原文本刊更多论文

0.01%和0.05%阿托品滴眼液治疗儿童近视进展的一年结果。

目的：比较0.01%和0.05%阿托品滴眼液与每隔一天治疗对减缓儿童近视进展的作用。方法：回顾性研究5 ~ 15岁近视-1.00 ~ 8.00屈光度(D)，散光小于-2.50 D，近一年内近视进展不低于1.00 D的儿童。0.01%、0.05%阿托品滴眼液每隔一天滴眼。每次就诊时，所有患者都接受了完整的眼科检查，包括睫状体屈光、眼轴长度（AL）和光-中视瞳孔大小。评估球形当量（SE）、AL和光致中观瞳孔大小。结果：共纳入46例患者92只眼（0.01%阿托品组22只，0.05%阿托品组24只）。随访12个月时，0.01%和0.05%阿托品组平均SE变化分别为-0.41±0.28和-0.19±0.22 D （P < 0.001）。0.01%和0.05%阿托品组AL变化分别为0.19±0.16和0.16±024 mm （P = 0.52）。0.01%阿托品组未见畏光、近视力模糊等不良反应，0.05%阿托品组畏光3例（12.5%），近视力模糊8例（33%）。结论：0.01%和0.05%阿托品滴眼液每隔一天使用可显著减缓近视的进展。0.01%阿托品的耐受性优于0.05%阿托品。[J].儿童眼斜视，2009；X(X):XXX-XXX。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pediatric Ophthalmology & Strabismus 医学-小儿科

CiteScore

1.80

自引率

8.30%

发文量

115

审稿时长

>12 weeks

期刊介绍： The Journal of Pediatric Ophthalmology & Strabismus is a bimonthly peer-reviewed publication for pediatric ophthalmologists. The Journal has published original articles on the diagnosis, treatment, and prevention of eye disorders in the pediatric age group and the treatment of strabismus in all age groups for over 50 years.